Omar MA El-Agnaf

668 total citations
8 papers, 500 citations indexed

About

Omar MA El-Agnaf is a scholar working on Neurology, Physiology and Molecular Biology. According to data from OpenAlex, Omar MA El-Agnaf has authored 8 papers receiving a total of 500 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Neurology, 4 papers in Physiology and 2 papers in Molecular Biology. Recurrent topics in Omar MA El-Agnaf's work include Parkinson's Disease Mechanisms and Treatments (5 papers), Neurological disorders and treatments (3 papers) and Alzheimer's disease research and treatments (3 papers). Omar MA El-Agnaf is often cited by papers focused on Parkinson's Disease Mechanisms and Treatments (5 papers), Neurological disorders and treatments (3 papers) and Alzheimer's disease research and treatments (3 papers). Omar MA El-Agnaf collaborates with scholars based in Qatar, United Arab Emirates and United Kingdom. Omar MA El-Agnaf's co-authors include Brit Mollenhauer, Claudia Trenkwalder, Michael G. Schlossmacher, Katrin Marcus, Min Li, Dominic M. Walsh, Elisabet Londos, Katarina Nägga, Mustafa T. Ardah and Kaj Blennow and has published in prestigious journals such as The Lancet Neurology, Journal of Neurochemistry and Neurobiology of Aging.

In The Last Decade

Omar MA El-Agnaf

8 papers receiving 499 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Omar MA El-Agnaf Qatar 6 333 238 111 93 70 8 500
Charles Duyckaerts France 7 220 0.7× 278 1.2× 143 1.3× 157 1.7× 81 1.2× 11 633
Amir Nazem United States 9 163 0.5× 207 0.9× 104 0.9× 97 1.0× 143 2.0× 13 635
Anna Oczkowska Poland 7 148 0.4× 184 0.8× 109 1.0× 194 2.1× 75 1.1× 13 496
Malin Johannesson Sweden 11 138 0.4× 350 1.5× 108 1.0× 165 1.8× 96 1.4× 16 595
Alessandro Mechelli Italy 8 262 0.8× 97 0.4× 142 1.3× 121 1.3× 78 1.1× 14 467
A. Tallón-Barranco Spain 14 174 0.5× 191 0.8× 106 1.0× 156 1.7× 56 0.8× 18 541
V. Chan-Palay Switzerland 6 119 0.4× 129 0.5× 139 1.3× 105 1.1× 64 0.9× 13 412
Q.-X. Li Australia 7 102 0.3× 206 0.9× 110 1.0× 138 1.5× 45 0.6× 10 386
Akiyoshi Morinaga Japan 11 106 0.3× 205 0.9× 76 0.7× 173 1.9× 47 0.7× 14 454
Michael Uebele Germany 5 342 1.0× 114 0.5× 39 0.4× 90 1.0× 77 1.1× 6 576

Countries citing papers authored by Omar MA El-Agnaf

Since Specialization
Citations

This map shows the geographic impact of Omar MA El-Agnaf's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Omar MA El-Agnaf with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Omar MA El-Agnaf more than expected).

Fields of papers citing papers by Omar MA El-Agnaf

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Omar MA El-Agnaf. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Omar MA El-Agnaf. The network helps show where Omar MA El-Agnaf may publish in the future.

Co-authorship network of co-authors of Omar MA El-Agnaf

This figure shows the co-authorship network connecting the top 25 collaborators of Omar MA El-Agnaf. A scholar is included among the top collaborators of Omar MA El-Agnaf based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Omar MA El-Agnaf. Omar MA El-Agnaf is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
1.
Vaikath, Nishant N., Issam Hmila, Vijay Gupta, et al.. (2019). Antibodies against alpha‐synuclein: tools and therapies. Journal of Neurochemistry. 150(5). 612–625. 47 indexed citations
2.
Kasai, Takashi, Ikuko Mizuta, Makoto Suematsu, et al.. (2017). Early-onset Parkinsonism in a pedigree with phosphoglycerate kinase deficiency and a heterozygous carrier: Do PGK-1 mutations contribute to vulnerability to Parkinsonism?. Journal of the Neurological Sciences. 381. 358–358. 2 indexed citations
3.
Kruse, Niels, Omar MA El-Agnaf, & Brit Mollenhauer. (2017). Validation of Electrochemiluminescence Assays for Highly Sensitive and Reproducible Quantification of α-Synuclein in Cerebrospinal Fluid. Bioanalysis. 9(8). 621–630. 11 indexed citations
4.
Hansson, Oskar, Sara Hall, Annika Öhrfelt, et al.. (2014). Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease. Alzheimer s Research & Therapy. 6(3). 25–25. 169 indexed citations
5.
Lu, Jiahong, Mustafa T. Ardah, Siva Sundara Kumar Durairajan, et al.. (2011). Baicalein Inhibits Formation of α‐Synuclein Oligomers within Living Cells and Prevents Aβ Peptide Fibrillation and Oligomerisation. ChemBioChem. 12(4). 615–624. 138 indexed citations
6.
Mollenhauer, Brit, Omar MA El-Agnaf, Katrin Marcus, Claudia Trenkwalder, & Michael G. Schlossmacher. (2010). Quantification of α-Synuclein in Cerebrospinal Fluid As a Biomarker Candidate: Review of the Literature and Considerations for Future Studies. Biomarkers in Medicine. 4(5). 683–699. 89 indexed citations
7.
El-Agnaf, Omar MA, Dominic M. Walsh, & David Allsop. (2003). Soluble oligomers for the diagnosis of neurodegenerative diseases. The Lancet Neurology. 2(8). 461–462. 43 indexed citations
8.
El-Agnaf, Omar MA, et al.. (2000). Conformation and toxicity of the ABRI peptide in familial British dementia. Neurobiology of Aging. 21. 110–110. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Charles Duyckaerts Breakdown of academic impact, for papers by Amir Nazem Breakdown of academic impact, for papers by Anna Oczkowska Breakdown of academic impact, for papers by Malin Johannesson Breakdown of academic impact, for papers by Alessandro Mechelli Breakdown of academic impact, for papers by A. Tallón-Barranco Breakdown of academic impact, for papers by V. Chan-Palay Breakdown of academic impact, for papers by Q.-X. Li Breakdown of academic impact, for papers by Akiyoshi Morinaga Breakdown of academic impact, for papers by Michael Uebele
Rankless by CCL
2026